ArticleBMC complementary and alternative medicine2016
Hypoglycaemic activity of ethanolic extract of Garcinia mangostana Linn. in normoglycaemic and streptozotocin-induced diabetic rats.
Article in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Hypoglycemic activity ofFrontiers in pharmacology · 2024Pooled it
- Mangosteen Extract Shows a Potent Insulin Sensitizing Effect in Obese Female Patients: A Prospective Randomized Controlled Pilot Study.Nutrients · 2018Trial
- Hypoglycemic and tissue protective effects of mangosteen (Garcinia mangostana L.) on diabetes associated periodontal tissue alterations.Odontology · 2026Article
- Comparative metabolomics of acetylcholinesterase and α-glucosidase inhibitors in pericarp of Garcinia mangostana L.Botanical studies · 2025Article
- Toxoplasma gondii modulates immune responses and mitigates type 1 diabetes progression in a streptozotocin-induced rat model.Cell communication and signaling : CCS · 2025Article
- Preparation and evaluation of a niosomal delivery system containingNanoscale advances · 2024Article
- A Mechanistic Review on Protective Effects of Mangosteen and its Xanthones Against Hazardous Materials and Toxins.Current neuropharmacology · 2024Review
- Identification of natural compound garcinone E as a novel autophagic flux inhibitor with anticancer effect in nasopharyngeal carcinoma cells.Pharmaceutical biology · 2023Article
- Antidotal and protective effects of mangosteen (Iranian journal of basic medical sciences · 2023Review
- Propolis and its constituents against cardiovascular risk factors including obesity, hypertension, atherosclerosis, diabetes, and dyslipidemia: A comprehensive review.Iranian journal of basic medical sciences · 2023Review
- The role of lutein-rich purple sweet potato leaf extract on the amelioration of diabetic retinopathy in streptozotocin-induced Sprague-Dawley rats.Frontiers in pharmacology · 2023Article
- Article
- Garcixanthone E and Garcimangophenone C: New Metabolites fromLife (Basel, Switzerland) · 2022Article
- Bioactivity-Guided Fractionation and Identification of Antidiabetic Compound ofMolecules (Basel, Switzerland) · 2022Article
- New Alpha-Amylase Inhibitory Metabolites from Pericarps ofLife (Basel, Switzerland) · 2022Article
- Mangostanin, a Xanthone Derived fromPharmaceuticals (Basel, Switzerland) · 2022Article
- Fabrication and Biological Assessment of Antidiabetic α-Mangostin Loaded Nanosponges: In Vitro, In Vivo, and In Silico Studies.Molecules (Basel, Switzerland) · 2021Article
- Effect ofBiomedical reports · 2021Article
- Anti-Acanthamoeba synergistic effect of chlorhexidine and Garcinia mangostana extract or α-mangostin against Acanthamoeba triangularis trophozoite and cyst forms.Scientific reports · 2021Article
- Alpha-mangostin improves endothelial dysfunction in db/db mice through inhibition of aSMase/ceramide pathway.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious parts of Garcinia mangostana Linn., including its pericarp, have been traditionally used to treat a variety of ailments. In an attempt to establish its medicinal value, the present study was carried out to determine the hypoglycaemic potential of G. mangostana pericarp ethanolic extract (GME) using the streptozotocin-induced (STZ) diabetic rats.
methodsGME at 2,000 mg/kg was subjected to a single-dose acute toxicity test. Following this, the effect of GME (50, 100, and 200 mg/kg) on blood glucose level of normoglycaemic and STZ-induced diabetic rats was determined using single-dose (acute) and multiple-dose (subacute) approaches. Subsequent to the multiple-dose study, serum biochemical analysis and liver histopathological examination were also performed. Throughout the experiments, the effect of GME was compared against the standard hypoglycaemic drug, glibenclamide.
resultsGME was safe for oral consumption up to the dose of 2,000 mg/kg. In both single- and multiple-dose studies, GME significantly (p < 0.05) reduced the blood glucose level in normoglycaemic rats and STZ-induced diabetic rats when compared against the normal control group or diabetic control group, respectively. Moreover, GME also significantly (p < 0.05) increased the rats' body weight in comparison to the diabetic control group in the multiple-dose study. GME also significantly (p < 0.05) reduced the levels of certain biochemical parameters [i.e., triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), very low density lipoprotein (VLDL), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), urea, and creatinine] while increased the others [i.e., high density lipoprotein (HDL) and total protein (TP)] when compared to the diabetic control group. Histopathological assessment of the collected liver revealed a mild increase in the population of β-cells in the diabetic rats.
conclusionGME exerts the hypoglycaemic activity possibly by increasing the population of insulin-producing β-cells. This activity could be attributed to the presence of antioxidant-bearing tannins like epicathecin, and xanthones like α-mangostin. Thus, the findings demonstrated that GME could be a potential candidate in the management of diabetes owing to its hypoglycaemic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.